Clinical trial
Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women…
NCT00499603 · M.D. Anderson Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00499603 |
|---|---|
| Title | Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer |
| Official title | Open Label Randomized Clinical Trial of Standard Neoadjuvant Chemotherapy (Paclitaxel Followed by FEC) Versus the Combination of Paclitaxel and RAD001 Followed by FEC in Women With Triple Receptor-Negative Breast Cancer (CRAD001C24101) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Industry National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Paclitaxel, 5-Fluorouracil, Epirubicin, Cyclophosphamide, RAD001 |
| Enrollment | 62 |
| Start date | Jul 1, 2007 |
| Primary completion | Apr 1, 2012 |
| Completion | Apr 1, 2017 |
| First posted | Jul 11, 2007 |
| Last update posted | Nov 1, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: